Table 4 Logit Models: Predicting Respondents Who Would Choose a Medicine for Susan
From: Preferences for breast cancer prevention among women with a BRCA1 or BRCA2 mutation
Characteristic | All Women (N = 587), OR (95% CI) | Women Assigned to See Susan Age 25 Years and Medicine 1, a Denosumab-Like Medicine (n = 285), OR (95% CI) | Women Assigned to See Susan Age 36 Years and Medicine 2, a Tamoxifen-Like Medicine (n = 302), OR (95% CI) |
|---|---|---|---|
Age 40 years or over | 0.983 (0.568–1.703) | 1.342 (0.636–2.831) | 0.656 (0.274–1.571) |
Hopes to have children in future (after mutation identified) or undecided | 1.054 (0.604–1.838) | 0.830 (0.378–1.823) | 1.347 (0.580–3.129) |
Time since genetic test | 1.000 (0.957–1.046) | 0.989 (0.929–1.052) | 1.015 (0.948–1.086) |
First-degree relative BC | 1.354 (0.898–2.040) | 1.072 (0.617–1.864) | 1.924* (1.017–3.638) |
First-degree relative OC | 1.049 (0.659–1.669) | 0.946 (0.496–1.807) | 1.378 (0.680–2.795) |
RRBM only | 0.806 (0.441–1.473) | 1.30 (0.545–3.392) | 0.485 (0.209–1.127) |
RRBSO only | 1.325 (0.692–2.539) | 1.915 (0.748–4.899) | 1.010 (0.387–2.637) |
RRBM and RRBSO | 0.851 (0.456–1.586) | 1.227 (0.503–2.993) | 0.607 (0.235–1.570) |
Higher education | 0.880 (0.588–1.316) | 1.325 (0.745–2.358) | 0.584 (0.321–1.064) |
Has taken a prescription medication, such as tamoxifen, raloxifene, or an aromatase inhibitor [anastrazole, exemestane] | 1.799 (0.840–3.855) | 0.850 (0.265–2.725) | 3.321* (1.129–9.771) |
Assigned to Susan, age 25 years | 1.500* (1.031–2.183) | Not applicable | Not applicable |